Results 81 to 90 of about 2,011 (173)

The prospects of cariprazine in the treatment of schizophrenia [PDF]

Therapeutic Advances in Psychopharmacology, 2017
openaire   +2 more sources

Bioequivalence evaluation of two cariprazine hard capsule formulations. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Rezk MR, Badr KA, Hosny AAEH, Abdel Magid AM.   +3 more
europepmc   +1 more source

New-Onset Gambling Addiction Following Treatment for Psychosis With Cariprazine. [PDF]

Cureus
Hashmi M, Nguyen A, Ilyas H.
europepmc   +1 more source

Tailoring cariprazine for dual disorders via secondary pharmacophore optimization. [PDF]

Eur J Med Chem
Vogt CD, Sanchez J, Bonifazi A, Saab E, Ranjit A, Rais R, Lane JR, Newman AH.   +7 more
europepmc   +1 more source

Clinical Practice Guideline on the Choice of First Antipsychotic Medicine for Females Experiencing a First-Episode of Psychosis. [PDF]

Schizophr Bull
Hynes-Ryan C, Keating D, Carolan A, Brand B, Dazzan P, Gaughran F, Hahn M, Halstead S, Harrington SM, Hartnett Y, Kelleher I, Lyne J, McNicholas F, O'Connor K, Perry B, Sadowska E, O'Donoghue B, Sommer IE.   +17 more
europepmc   +1 more source

Third-Generation Antipsychotics as Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Narrative Review of Efficacy and Tolerability. [PDF]

Biomedicines
Rosso G, Peracchia S, Rizzo Pesci N, Di Salvo G, Maina G.   +4 more
europepmc   +1 more source

Editorial: Women with neuropsychiatric disorders: understanding & personalizing needs. [PDF]

Front Psychiatry
Barabássy Á, Dombi ZB, Gemzell-Danielsson K, Molnar MJ.   +3 more
europepmc   +1 more source

Rational antipsychotic polypharmacy in psychotic and bipolar disorders: A focus on D2 receptor partial agonists. [PDF]

Ment Health Clin
Salwan A.
europepmc   +1 more source

Severe Nondiabetic Hypoglycemia After Risperidone Initiation in an Adult With Schizophrenia: A Case Report and Systematic Review. [PDF]

Cureus
Sarker A, Yusuf M, Gillespie M.
europepmc   +1 more source

Partial agonist antipsychotic drugs differentially interact with a secondary binding site at the dopamine D2 receptor. [PDF]

Int J Neuropsychopharmacol
Ågren R, Sahlholm K.
europepmc   +1 more source